TG Therapeutics, Inc. (TGTX)
| Market Cap | 743.84M |
| Revenue (ttm) | 7.91M |
| Net Income (ttm) | -326.49M |
| Shares Out | 144.43M |
| EPS (ttm) | -2.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,076,605 |
| Open | 5.07 |
| Previous Close | 5.05 |
| Day's Range | 4.74 - 5.19 |
| 52-Week Range | 4.73 - 41.00 |
| Beta | 2.24 |
| Analysts | Buy |
| Price Target | 19.96 (+287.6%) |
| Earnings Date | May 23, 2022 |
About TGTX
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymph...
Financial Performance
In 2021, TGTX's revenue was $6.69 million, an increase of 4,300.66% compared to the previous year's $152,000. Losses were -$348.10 million, 24.6% more than in 2020.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for TGTX stock is "Buy." The 12-month stock price forecast is 19.96, which is an increase of 287.57% from the latest price.
News
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Scler...
NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, including one oral and two poster presentations, highlighting data fr...
TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
Presentation available for on demand download beginning Tuesday May 24, 2022 at 7:00 AM ET Presentation available for on demand download beginning Tuesday May 24, 2022 at 7:00 AM ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX
NEW YORK , May 11, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TG Therapeutics, Inc. ("TG Therapeutics" or the "Company") (NASDAQ: TGTX). Such investors are advi...
5 Graham's Lost Formula Biotech Stocks to Consider for May
After a brutal month in April, U.S. market indexes were lower on Tuesday as investors await the Federal Open Market Committee's decision on interest rates.
Will TG Therapeutics (TGTX) Report Negative Q1 Earnings? What You Should Know
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics to Participate in the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference
Fireside chat scheduled for Thursday, April 28, 2022 at 12:30 PM ET Fireside chat scheduled for Thursday, April 28, 2022 at 12:30 PM ET
TG Therapeutics (TGTX) Withdraws FDA Submission, Stock Down
TG Therapeutics (TGTX) voluntarily withdraws regulatory application seeking approval for the combination regimen, ublituximab plus Ukoniq. It also withdraws Ukoniq from sale in approved indications.
Despite Price Cut, HC Wainwright Keeps Buy Rating On TG Therapeutics - Read Why
TG Therapeutics Inc's (NASDAQ: TGTX) shares are plunging after new data showed that ublituximab /Ukoniq showed an elevated risk of death in the phase 3 Unity combo trial for chronic lymphocytic leukemia...
TG Therapeutics to pull FDA submission for oncology drug; shares slid 24%
Shares of TG Therapeutics Inc. TGTX, -21.85% tumbled 24.2% in trading on Monday following the company's announcement on Friday that it had withdrawn an application to get Food and Drug Administration ap...
Why TG Therapeutics Stock Is Plunging Today
TG Therapeutics Inc (NASDAQ: TGTX) shares are trading significantly lower Monday morning after the company announced it has voluntarily withdrawn the pending Biologics License Application/supplemental N...
TG Therapeutics Retracts FDA Request For Ublituximab / Ukoniq Combo In Blood Cancers
TG Therapeutics Inc's (NASDAQ: TGTX) new data showed that ublituximab /Ukoniq, dubbed U2, had an elevated risk of death in the phase 3 Unity combo trial or chronic lymphocytic leukemia (CLL) and small l...
TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL
Company voluntarily withdraws UKONIQ ® from sale for approved indications of relapsed/refractory MZL and FL Company to host conference call, Monday, April 18, 2022 at 8:30 AM ET NEW YORK, April 15, 2022...
5 Key FDA Decisions Could Affect Drug Stocks
If readouts on clinical trials can impact the stocks of pharma companies, the Food and Drug Administration (FDA) decisions on whether or not specific drugs are approved can affect not only the stock pri...
TG Therapeutics Announces Oral Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multipl...
NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing for...
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Scler...
NEW YORK, April 04, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of...
TG Therapeutics Announces Scheduling of Planned Oncologic Drug Advisory Committee Meeting
FDA schedules ODAC meeting for April 22, 2022 FDA schedules ODAC meeting for April 22, 2022
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Scler...
NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, including one oral and three poster presentations, highlighting dat...
FDA Pushes TG Therapeutics' Ublituximab / Ukoniq Combo Therapy Applications In Blood Cancer Settings
The FDA has extended the review period of TG Therapeutics Inc's (NASDAQ: TGTX) biologics license application and supplemental New Drug Application for ublituximab in combination with Ukoniq (umbralisib)...
TG Therapeutics Announces Extension of U.S. FDA BLA/sNDA PDUFA Date for Ublituximab Plus UKONIQ® (U2) to Treat Patien...
FDA sets updated PDUFA goal date of June 25, 2022 FDA sets updated PDUFA goal date of June 25, 2022
TG Therapeutics (TGTX) Reports Q4 Loss, Lags Revenue Estimates
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -12.90% and 76.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results
Conference call to be held today, Tuesday, March 1, 2022, at 8:30 AM ET Conference call to be held today, Tuesday, March 1, 2022, at 8:30 AM ET
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Scler...
NEW YORK, Feb. 25, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) ...
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2021 Financial Results and Business Update
Conference call to be held Tuesday, March 1, 2022 at 8:30 AM ET Conference call to be held Tuesday, March 1, 2022 at 8:30 AM ET
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Scler...
NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating...